



ASX ANNOUNCEMENT

Extension of Share Purchase Plan

Melbourne, Australia; 20 October 2014: Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) advises that it has extended the closing date of its share purchase plan (SPP) following the release today of preliminary positive DEP™ docetaxel pharmacokinetic (PK) findings from its Phase I clinical trial.

The extension is intended to provide eligible shareholders* with the opportunity to consider today's DEP™ docetaxel PK data announcement and the significance of these data, and in view of the existing closing date, to provide eligible shareholders with sufficient time to respond.

The SPP was due to close on Tuesday, 21 October 2014 and will now close at 5 pm (Melbourne time) on Wednesday, 29 October 2014.

Starpharma also confirms that all eligible (Australian) directors will participate in the SPP.

No action is required to be taken by shareholders who have already made application for shares under the SPP. However if you wish to increase your participation, promptly telephone Starpharma's shareholder information line on 1300 722 706 (within Australia) or +61 3 9415 4347 (outside Australia).

The other terms of the SPP, including the price of A\$0.65 per share and the maximum application value of A\$15,000 per shareholder, remain as set out in the offer document mailed to shareholders on 26 September 2014. The revised timetable of key dates for the SPP is now as follows (all times are Melbourne time):

| | |
|--|---------------------------------|
| Record Date | 7 pm, Friday 19 September 2014 |
| Opening Date | Monday 29 September 2014 |
| Closing Date | 5 pm, Wednesday 29 October 2014 |
| Allotment of Shares | Wednesday 5 November 2014 |
| Trading of New Shares expected to commence on ASX | Thursday 6 November 2014 |
| Holding statements expected to be dispatched to shareholders | Monday 10 November 2014 |

You may contact Starpharma's shareholder information line, on 1300 722 706 (within Australia) or +61 3 9415 4347 (outside Australia) if you have any queries in relation to the SPP.

*As previously advised, Australian and New Zealand registered shareholders who held shares at 7 pm (Melbourne time) on the record date of 19 September 2014 are eligible to participate in the SPP.

ABOUT STARPHARMA

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma's underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and medical uses. Starpharma has three core development programs: VivaGel® portfolio, drug delivery, and agrochemicals with the Company developing a number of products internally and others via commercial partnerships.

Starpharma's lead products are based on VivaGel® (SPL7013, astodimer sodium), a proprietary dendrimer which is a potent microbicidal agent. VivaGel® formulated as a water based gel and delivered vaginally is under clinical development for the management and prevention of bacterial vaginosis (BV). Starpharma has also signed separate licence agreements with Ansell Limited (ASX:ANN) and Okamoto Industries, Inc., (TSE: JP3192800005) to market a value-added, VivaGel® condom. Okamoto is the market leader for condoms sold in Japan, which is the world's second largest condom market. Ansell manufactures and sells leading condom brands worldwide, including LifeStyles®, ZERO® and SKYN®.

In the wider pharmaceutical and life science fields, Starpharma has both partnered and internal programs in Drug Delivery. Drug Delivery partners include GSK, Lilly and AstraZeneca. A number of dendrimer-enhanced, or DEP™ versions of existing drugs are under development. The most advanced of these is DEP™ docetaxel, a dendrimer-enhanced version of docetaxel (Taxotere®), which is in clinical development. In preclinical studies DEP™ docetaxel has shown significant tumour-targeting and superior anti-cancer effects across a range of important cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere® (docetaxel).

In agrochemicals Starpharma has a series of partnerships with leading industry players including global leader Adama (formerly Makhteshim Agan) as well as internal programs including an enhanced version of glyphosate (the active ingredient in Roundup®).

FOR FURTHER INFORMATION

Media:

Buchan Consulting

Rebecca Wilson

Mob: +61 417 382 391

rwilson@buchanwe.com.au

Starpharma:

Dr Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and Company Secretary

+61 3 8532 2704

investor.relations@starpharma.com

www.starpharma.com

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.